BERKELEY, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will participate in an analyst led fireside chat at the Leerink Partners Immuno-Oncology Roundtable on Thursday, October 1, 2015, at 10:55 am Eastern Time.
To access the live webcasts and subsequent archived recordings of the company's presentations, please visit Aduro's website at www.aduro.com.
Aduro Biotech, Inc. is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. Aduro's lead platform is based on proprietary strains of live-attenuated, double-deleted (LADD) Listeria monocytogenes that induce a potent innate immune response and have been engineered to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. Aduro has received Breakthrough Therapy designation from the FDA for its lead LADD regimen, CRS-207 in combination with GVAX Pancreas in pancreatic cancer. The company is evaluating the proprietary immuno-oncology combination in the ongoing Phase 2b ECLIPSE clinical trial and has additional ongoing clinical trials with its LADD platform in mesothelioma and glioblastoma. The company is also developing clinical candidates using cyclic dinucleotide (CDN) synthetic small molecule immune modulators that are designed to activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit www.aduro.com.
CONTACT: Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
925 202 6211